Photo from archive.org
Recent therapeutic innovations are significantly changing the management of young children with severe haemophilia. A team from the University Hospital of Nice (06) introduced emicizumab, the first subcutaneous non-replacement therapy.… Click to show full abstract
Recent therapeutic innovations are significantly changing the management of young children with severe haemophilia. A team from the University Hospital of Nice (06) introduced emicizumab, the first subcutaneous non-replacement therapy. Integrated into the multi-professional management of children and their families, this innovative therapeutic option has shown encouraging initial results. Experience sharing.
Keywords:
haemophilia;
practice changes;
management;
major paediatric;
management major;
changes management
Journal Title: Revue de l'infirmiere
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Revue de l'infirmiere
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!